Liraglutide
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Novo Nordisk · Phase 2 · Completed · Enrollment 706
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| NNC0174-0833, 4.5 mg | Obesity or overweight | 4.5 mg | 26 | n/r | n/r |
| NNC0174-0833, 2.4 mg | Obesity or overweight | 2.4 mg | 26 | n/r | n/r |
| NNC0174-0833, 1.2 mg | Obesity or overweight | 1.2 mg | 26 | n/r | n/r |
| NNC0174-0833, 0.6 mg | Obesity or overweight | 0.6 mg | 26 | n/r | n/r |
| NNC0174-0833 0.3 mg | Obesity or overweight | 0.3 mg | 26 | n/r | n/r |
| Placebo 2.4 mg (NNC0174-0833) | Obesity or overweight | 2.4 mg | 26 | ITT | n/r |
| Placebo 4.5 mg (NNC0174-0833) | Obesity or overweight | 4.5 mg | 26 | ITT | n/r |
| Placebo 1.2 mg (NNC0174-0833) | Obesity or overweight | 1.2 mg | 26 | ITT | n/r |
| Placebo 0.6 mg (NNC0174-0833) | Obesity or overweight | 0.6 mg | 26 | ITT | n/r |
| Placebo 0.3 mg (NNC0174-0833) | Obesity or overweight | 0.3 mg | 26 | ITT | n/r |
| Liraglutide 3.0 mg | Obesity or overweight | 3.0 mg | 26 | ITT | n/r |
| Placebo 3.0 mg (Liraglutide) | Obesity or overweight | 3.0 mg | 26 | ITT | n/r |